NLA and Insilico Medicine to develop integrated biomarkers of human aging

May 17, 2016

InsilicoAstana, 17 may, 2016. Insilico Medicine announced an agreement with National Laboratory Astana, Nazarbayev University, one of the most rapidly growing universities in the world to collaboratively study aging and age-associated pathologies.

“We are very happy to collaborate with Insilico Medicine, one of the leaders in applying artificial intelligence to aging research. At the Nazarbayev University we are generating vast amounts of data, including next generation sequencing, gut microbiome, genomic  and metabolomic data.  Healthy aging and healthspan extension  is one of our main research priorities. Deep learning has revolutionized many areas including image and text recognition and is likely to advance many areas of biomedicine,” said Zhaxybay Zhumadilov, General Director  of the National Laboratory Astana, Nazarbayev University.

In the scope of the agreement, Insilico Medicine will provide advanced signaling pathway activation analysis services to evaluate differential changes between healthy tissues and those affected by disease as well as comparing tissues of different ages. In addition to signaling pathway analysis, parties intend to develop artificially-intelligent comprehensive biomarkers of human aging based on large sample data sets.

“Nazarbayev University is one of the most advanced universities in Eastern Europe and Central Asia with state of the art equipment and highly qualified staff educated in top international universities. This institution is scouting for cutting-edge technologies and Insilico Medicine is delighted to be selected as one of the providers of high-technology solutions for longevity research,” said Alex Zhavoronkov, CEO  of Insilico Medicine. Inc, who was one of the speakers of the  recently past  the IV International conference on regenerative medicine and healthy aging, held at the National Laboratory Astana on 11-12 May, 2016.  

About Insilico Medicine

Insilico Medicine, Inc. is a bioinformatics company located at the Emerging Technology Centers at the Johns Hopkins University Eastern campus in Baltimore with R&D resources in Belgium, Russia and Poland hiring talent through hackathons and competitions. It utilizes advances in genomics, big data analysis and deep learning for in silico drug discovery and drug repurposing for aging and age-related diseases. The company pursues internal drug discovery programs in cancer, Parkinson's, Alzheimer's, sarcopenia and geroprotector discovery. Through its Pharma.AI division the company provides advanced machine learning services to biotechnology, pharmaceutical and skin care companies.  Brief company video: